Novo Nordisk (NYSE: NVO) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning ...
CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
As Heart Month reminds us of the critical need to protect our cardiovascular and metabolic (CVM) health, Novo Nordisk ...
GlobalData on MSN4d
AbbVie enters obesity space with $2.3bn Gubra dealAbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback